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Abstract:
Selective Immunoglobulin A Deficiency (SIgAD) is the most common 
primary immunodeficiency, defined as an isolated deficiency of IgA 
(less than 0.07 g/L).  Although the majority of people born with IgA 
deficiency lead normal lives without significant pathology, there is 
nonetheless a significant association of IgA deficiency with mucosal 
infection, increased risks of atopic disease, and a higher prevalence of 
autoimmune disease. To explain these phenomena, we have 
performed an extensive literature review to define the 
geoepidemiology of IgA deficiency and particularly the relative risks for
developing Systemic Lupus Erythematosus, hyperthyroidism, 
hypothyroidism, type 1 diabetes mellitus, Crohn’s Disease, ulcerative 
colitis, rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing 
spondylitis, and vitiligo; these diseases have strong data to support an 
association. We also note weaker associations with scleroderma, celiac
disease, autoimmune hepatitis, immune thrombocytopenic purpura, 
and autoimmune hemolytic anemia. Minimal if any associations are 
noted with myasthenia gravis, lichen planus, and multiple sclerosis. 
Finally, more recent data provide clues on the possible immunologic 
mechanisms that lead to the association of IgA deficiency and 
autoimmunity; these lessons are important for understanding the 
etiology of autoimmune disease.
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Introduction:
Selective Immunoglobulin A Deficiency (SIgAD) is a relatively common 
primary immunodeficiency which is associated with a number of 
clinically significant complications. Interestingly, autoimmune 
conditions are more common among SIgAD populations. This review 
touches on proposed mechanisms for the development of SIgAD and 
its complications, and then summarizes the current data regarding 
autoimmune conditions in individuals with this disease.
Diagnostic Criteria:
Selective Immunoglobulin A Deficiency (SIgAD) is defined as 
immunoglobulin A (IgA) levels less than 0.07g/L in a patient four years 
of age or older with normal immunoglobulin M (IgM) and 
immunoglobulin G (IgG), and no other identified causes of 
immunodeficiency.[1,2] This standardized definition is useful for 
clinical and research applications, but assumes that normal IgA levels 
are similar across all demographics – an inaccurate assumption. Data 
regarding IgA levels in healthy populations are limited, but have shown
that average IgA levels increase by 20 mg/dL per decade in women, 
and are generally higher in male populations than female.[3] IgA levels
vary to such an extent with ethnicity and seasons that the prevalence 
of SIgAD falls during winter months.[3] This raises questions about the 
validity of current SIgAD diagnostic criteria, because the same patient 
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may have SIgAD when measured in summer, but not in winter.[4,5] 
Seasonal variation may be caused by increased exposure to pathogens
in the winter, resulting in stimulation of the immune system. It should 
be noted that this seasonal variation was not seen in a large study of 
Nigerians which did find IgA variability with age and sex.[6] IgA levels 
are also known to be associated with metabolic syndrome, heavy 
drinking, and liver fibrosis.[7,8]
It is also important to note that the definition of SIgAD has changed 
over time. Indeed, the scientific community did not reach consensus on
a single definition of SIgAD until 1999.[9] Prior studies have identified 
individuals with SIgAD using variable IgA cutoff values, meaning that 
some older studies may have included individuals without the disease 
or excluded patients with the disease under the current definition.
Epidemiology:
SIgAD is the most prevalent primary immunodeficiency, found at the 
highest frequency of 1 in 142 in Caucasians, and a low of 1 in 18,550 
among Japanese, with a prevalence among other ethnicities ranging 
between these values.[1,3,10-13] Genetic factors likely play a role in 
the development of SIgAD, as 33.3% of patients are from 
consanguineous unions.[1] The disease does not follow simple 
mendelian inheritance patterns, but does exhibit familial clustering. For
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example the general SIgAD prevalence among Turkish individuals is 1 
in 188, compared to 1 in 34 among 1st degree relatives of Turkish 
individuals with SIgAD.[14] Additionally, 20-25% of SIgAD patients 
have a family history of SIgAD or CVID.[2] Although IgA levels are 
typically higher in males, men are more likely to have SIgAD (0.28% in 
men, compared to 0.04% in women).[3]
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Function and Structure of IgA
Two thirds of all immunoglobulin produced by the body is IgA, which 
has an important role in both humoral and mucosal immunity.[15] In 
humans, IgA exists in two forms – IgA1 and IgA2, with the former more 
common in blood, and the latter primarily in secretions.[16] Both types
may exist in a membrane-bound form, free monomeric form, or free 
dimeric form. The free, monomeric form is dominant in the serum, 
whereas the dimeric form is most common in secretions. The dimeric 
form is wrapped by the secretory component – a cleaved portion of the
polymeric immunoglobulin receptor that prevents breakdown of 
secreted IgA by proteases and gastric acid in the gastrointestinal 
system.[16] In its various forms, IgA binds antigens on bacteria, 
viruses, and various toxins to prevent their action at the mucosal 
barrier, exerts an anti-inflammatory effect, and has been noted in 
mouse models to influence the intestinal microbiota by binding non-
beneficial bacteria and inhibiting their growth, while allowing beneficial
bacteria such as Lactobacillus casei to proliferate.[15,17]  
Complications:
An increased risk of infections has been widely reported in IgA 
deficiency, most commonly in the form of mucosal infections. One 
study found pneumonia in 57.8% of children with SIgAD (compared to 
7
an annual incidence of community acquired pneumonia in the United 
States of 24.8 per 10,000 persons), recurrent infections in 24.5%, and 
bronchiectasis in 14.0% (compared to an estimated prevalence of 37-
56.6 per 10,000 persons).[1,18,19] This study relied upon caregivers to
report diagnoses in a questionnaire. A separate study found 17.5% of 
children with SIgAD had recurrent URIs, 11.8% had recurrent otitis, 
17.8% had pneumonia, and 6.0% had recurrent pneumonia.[20] 
However, this study did not provide a definition of recurrent URIs, 
recurrent otitis, or recurrent pneumonia, making it difficult to compare 
the reported prevalence with the population-level prevalence, 
particularly when as many as 46% of children in the general population
have three or more episodes of otitis media by three years of age.[21] 
In another study, the prevalence of recurrent URI (defined as 3 
episodes per year for 3 successive years) and recurrent UTI (defined as
3 episodes over a 2 year period) was 42% and 9%, respectively, 
among patients with SIgAD, compared to 29% and 3% among 
individuals with normal IgA levels.[22] In addition to the increased 
frequency of minor infections observed among patients with SIgAD, the
authors also noted a significantly increased incidence of serious 
infections and complications, including pulmonary tuberculosis and 
septicemia.[22] Fungal hair and nail infections are seen in 56.3% of 
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individuals with SIgAD, which is significantly more common than the 
20.6% in the general population.[23].  
IgA Deficiency, Allergy, and Atopy:
SIgAD is associated with increased prevalence of allergies in patients, 
as well as their first degree relatives, although this pattern does not 
bear out in all studies.[24] According to one pediatric study, 18.78% of
SIgAD patients exhibited allergic sequalae (12.1% asthma, 8.8% 
rhinitis, 3.6% atopic dermatitis, and 4.2% food allergy), with 11.46% 
undergoing adenoidectomy compared to 1.14% of the general 
population over the same period.[20] In comparison, population 
studies have shown that 5-7% of children in the general population 
have asthma, and 5-12% have rhinitis.[25] Atopic dermatitis has such 
a variable range of diagnostic criteria among studies that prevalence 
estimates in the general population vary so much as to be 
meaningless.[26] Another study showed allergiesin 56% of individuals 
with SIgAD, and asthma in 29.8%.[1] A study of only 39 cases 
calculated an odds ratio 3.57 (23%) for having asthma among known 
SIgAD patients.[27] Among Turkish pediatric patients, 45.7% had an 
allergic disorder (34.6% asthma, 27.2% allergic rhinitis, 11.1% atopic 
dermatitis, 22.2% positive skin prick), and among their first degree 
relatives, 10.9% had asthma, 9.1% had allergic rhinitis, and 7.7% had 
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eczema.[14] One study of SIgAD patients found that 57.84% had 
atopic dermatitis, although only 10.17% of those had elevated IgE.[28]
These studies are generally small, yielding significant variability 
between resulting prevalence estimates. Although the literature would
benefit from larger population studies, the existing data  suggest that 
allergic symptoms are more common both in patients with SIgAD and 
their first degree relatives.
IgA Deficiency and Anaphylactic Transfusion Reactions:
For decades, the most feared ramification of SIgAD has been the 
potential for anaphylactic transfusion reactions. Anti-IgA IgE antibodies
have been reported in individuals with SIgAD, suggesting the 
possibility of anaphylactic reactions to blood or IVIG transfusions to 
sensitized patients. The incidence of such reactions was originally 
reported as 1 in 20,000-47,000 transfusions.[13,29] At great cost, 
many hospitals created vigilance schemes to provide IgA deficient 
patients with only blood products that were donated by IgA deficient 
donors, or that were washed of IgA. IgA was effectively removed from 
blood products via washing with buffered saline solutions.[30] Recent 
findings have cast doubt on the existence of such transfusion 
reactions, however. Only 17.0% of reported cases were found to have 
anti-IgA antibodies; many reported cases have subsequently been 
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transfused IgA containing products without experiencing a repeat 
reaction; and IgA deficiency is not more common among patients who 
have had anaphylactic transfusion reactions.[31] This evidence 
suggests that if SIgAD-related anaphylactic transfusion reactions 
occur, they are less common than previously believed. Additional 
research is needed to determine conclusively whether SIgAD is truly a 
cause of anaphylactic transfusion reactions. While it may be safe to 
give IgA-containing blood to IgA deficient individuals, until more 
information is available, this should be done carefully and with close 
monitoring. Patients with a suspected history of SIgAD-related 
transfusion reactions should not be given IgA-containing blood 
products.
IgA Deficiency and CVID:
In some cases, SIgAD has also been observed to progress to Common 
Variable Immunodeficiency (CVID).[32] Interestingly, one study 
showed that 23.5% of SIgAD patients with autoimmunity progressed to
CVID, while none of the SIgAD patients without autoimmunity did.[1] 
However, diagnostic uncertainty makes it impossible to determine 
whether these patients had true SIgAD progressing to CVID, or simply 
subclinical CVID that progressed over time.
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IgA Deficiency and Gastrointestinal Disease:
SIgAD has also been associated with lactase deficiency. 21% of 
individuals with SIgAD had confirmed or presumed lactase deficiency, 
versus 8% of individuals with normal levels of IgA in one study.[22] 
SIgAD does not appear to be associated with H. pylori associated 
dyspepsia, but among patients with symptomatic H. pylori dyspepsia, 
those with SIgAD have a significantly higher incidence of gastritis, 
duodenal ulcers, and nodular lymphoid hyperplasia.[33] 
Nodular lymphoid hyperplasia (NLH) has been noted in individuals with
SIgAD, but it is difficult to determine whether this is a true association 
because NLH is asymptomatic in most cases, and therefore may go 
undiagnosed in the absence of other GI pathology. It is also known to 
be associated with Giardia lamblia infection and celiac disease, two 
conditions that are more common among individuals with SIgAD, 
further clouding the picture.[34,35] Many case reports have suggested
a possible association, but no studies of prevalence have been 
published to date.[36]
Both recurrent and chronic diarrhea are significantly more common 
among individuals with SIgAD, but many of these cases may be 
associated with Celiac disease or inflammatory bowel disease, which 
will be covered more thoroughly below.[20]
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IgA Deficiency and Malignancy:
Although other primary immunodeficiencies have been associated 
with higher rates of malignancy, the data regarding SIgAD is limited. 
One study of Spaniards with SIgAD revealed a prevalence of 1.5% for a
subset of malignancies including Hodgkin lymphoma, ALL, Wilm’s, 
Burkitt’s, and ganglioneuroma.[20] A second study of 386 patients 
with SIgAD found a small increase in incidence of cancer compared to 
a healthy cohort, but the increase was nonsignificant.[37]
IgA Deficiency and Quality of Life:
One small study found individuals with SIgAD to have lower average 
health-related quality of life.[38] Risk factors for lower quality of life 
scores within the SIgAD cohort included higher number of antibiotic 
treatments in the past year, higher number of daily medications, 
allergic rhinoconjunctivitis, chronic MSK symptoms at least every other
week, and anxiety or insomnia.
Despite its known association with autoimmune diseases and its 
putative link with malignancies, SIgAD does not appear to significantly
affect mortality, and it has a better prognosis than other primary 
antibody deficiencies.[22,39]
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IgA Deficiency and Autoimmunity:
Perhaps the most interesting feature of SIgAD is its association with 
various autoimmune conditions. Between 25.5 and 31.7% of 
individuals with SIgAD are afflicted with an autoimmune condition.
[1,40,41] A study of Turkish children with SIgAD found autoimmune 
manifestations in only 17.3%, possibly because autoimmunity has less 
time to manifest in these young individuals.[14]
Individuals with SIgAD are also more likely to have family members 
with autoimmune disorders than healthy controls. In the 
aforementioned Turkish study, 14.6% of the first degree relatives of 
children with SIgAD had autoimmune disorders, compared to 5% of the
general population.[14] A second study found that 17.5% of SIgAD 
individuals had first or second degree relatives with autoimmune 
disorders.[1] Notably, the authors found that a family history of 
autoimmunity or primary immunodeficiency did not predict whether a 
given individual with SIgAD would develop autoimmune 
manifestations. However, not all studies have borne out the same 
pattern. One study of Spaniards with SIgAD found that only 2.16% of 
them had a family history of autoimmunity.[20]
Interestingly, some studies have suggested a substantive difference 
between SIgAD individuals who develop autoimmunity and those who 
do not. One study of 57 patients with symptomatic SIgAD found that 
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mean serum level of IgM significantly higher, regulatory T cell count 
was lower, and switched memory B cell count was lower in patients 
with autoimmunity, compared to patients without autoimmunity.[1] 
The same study noted that 76.4% of those individuals with 
autoimmunity exhibited a class switching defect, versus 5% of SIgAD 
cases without autoimmunity. Unfortunately, the mechanism of 
autoimmunity in SIgAD remains unknown. (Table 1)
Although there is a clear correlation between SIgAD and autoimmunity,
not all autoimmune diseases are associated with SIgAD. While a 
number of studies have examined the prevalence of specific 
autoimmune diseases among individuals with SIgAD, small study 
populations lead to significant variability of results. The following is a 
summary of the available data.
Mechanisms of Autoimmunity in IgA Deficiency
Previous papers have suggested six possible mechanisms for the 
increased incidence of autoimmunity in individuals with SIgAD, 
although the mechanisms are not mutually exclusive, and multiple 
mechanisms are likely at play simultaneously (Table 1).[42] 
The first hypothesis suggests that certain human leukocyte antigens 
(HLA) genes on the MHC locus of chromosome 6 favor the 
development of both SIgAD and autoimmune diseases. The pattern of 
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familial clustering observed in SIgAD is a strong argument in favor of 
this hypothesis.[43] An inordinate proportion of patients with SIgAD 
express haplotype 8.1 (HLA-A1, B8, DR3, DQ2) (45% of SIgAD patients,
compared to 16% of general population). Others have noted that HLA-
DR7, DQ2 and HLA-DR1, DQ5 are also more prevalent among SIgAD 
patients, compared to the general population.[13,44-48] Many of the 
HLA types that appear frequently in SIgAD patients overlap with those 
commonly observed in autoimmune diseases, including celiac disease, 
type 1 diabetes mellitus, systemic lupus erythematosus, and Grave’s 
disease.[49] However, a large Swedish study demonstrated no 
appreciable difference between HLA frequencies in SIgAD versus 
healthy individuals.[50]
A second proposed mechanism suggests that both SIgAD and 
autoimmunity may arise secondary to the same B cell, T cell, or 
cytokine abnormalities. Regulatory T cell deficiency is very common in 
SIgAD (prevalence of 64%) and is also associated with autoimmunity.
[40] Abolhassani et al. observed that SIgAD complicated by 
autoimmunity had fewer regulatory T cells, as well as CD27+ IgD- 
memory B cells, compared to SIgAD without autoimmunity.[1] On the 
other hand, Nechvatalova and colleagues found that patients with 
SIgAD had greater numbers of regulatory T cells and differentiated 
memory T cells, compared to healthy individuals, although the findings
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may be due to the higher rate of CMV infection among SIgAD patients 
in this study.[51] In another study, the same group found lower 
numbers of CD4+ lymphocytes and switched memory B cells, similar 
to the patterns commonly observed in CVID patients.[52] Another 
study observed that SIgAD patients with lower numbers of switched 
memory B cells was more prone to infection and autoimmunity.[53] 
Indeed, over one quarter of individuals with SIgAD also have low levels 
of IgG3 or IgG4, and low IgG2 has also been observed in this 
population suggesting possible subclinical B cell abnormalities.[54,55] 
Borte, Lio, and colleagues demonstrated an increase in IgA production 
in SIgAD patients after stimulation with certain cytokines, arguing for 
the existence of a class-switching defect.[56,57] Indeed, one study 
found that 76.4% SIgAD cases complicated by autoimmunity had a 
class-switching defect, compared to 5% of SIgAD cases without 
autoimmunity.[1] However, other studies have noted the existence of 
immature IgA positive B cells in SIgAD patients, suggesting that in 
some cases the defect is in maturation, rather than class switching of B
cells.[58] T and B cells have a higher rate of spontaneous and induced 
apoptosis in patients with CVID, and Yazdani and colleagues have 
recently suggested that the same mechanism may be present in those 
with SIgAD, although this mechanism has yet to be confirmed in 
individuals with SIgAD.[59] Additionally, SIgAD has been transferred 
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between patients via bone marrow grafting, which further suggests a 
defect in immune cells.[46] 
The monogenic hypothesis suggests that certain as-yet undiscovered 
monogenic mutations predispose both to the development of SIgAD 
and autoimmune conditions. Researchers have observed that certain 
primary immunodeficiency syndromes are secondary to monogenic 
mutations that predispose the same patients to autoimmune 
manifestations.[10] Bronson and colleagues noted several monogenic 
associations between SIgAD and autoimmune disease in a genome-
wide study.[60] Another paper found a similar variant of CTLA4-ICOS 
common in celiac disease, SIgAD, and CVID.[61] Mutations in the TACI 
gene have also been implicated in certain cases of SIgAD.[58] While 
this mechanism may be at play for certain associations, no single 
mutation has yet been found to explain the correlation of SIgAD with 
any specific autoimmune disease, or autoimmunity in general. If a 
single gene mutation associated with SIgAD predisposes to 
autoimmunity, it appears that additional mechanisms must also be at 
play for any individual to develop autoimmune manifestations.
The fourth hypothesis is more specific to the functions of IgA, which 
protects mucosal barriers from entry of foreign pathogens and 
antigens. Studies have clearly established that rates of infection and 
atopy are higher among patients with SIgAD, suggesting greater 
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mucosal permeability to pathogens and antigens, likely due to the lack 
of IgA to bind them.[1,14,20,22-24,27,28] Because a greater number of
foreign antigens cross the mucosal barrier in the setting of SIgAD, B 
and T cells will become sensitized to a greater number of antigenic 
combinations, which may place patients at increased risk for the 
development of autoimmune disease. Exposure to infectious agents is 
known to induce autoimmune disease in some circumstances – 
important examples being the molecular mimicry of cardiac myosin by 
group A streptococci causing rheumatic fever, HLA-B27 by Klebsiella 
pneumoniae causing spondyloarthropathies, and peripheral nerve 
antigens by Campylobacter jejuni causing Guillain-Barré, among 
others.[62,63] Indeed, T cells may become autoreactive and initiate 
autoimmune disease via molecular mimicry, when the same TCR is 
capable of recognizing both a foreign antigen and a self antigen, 
expression of two distinct T cell receptors (TCRs) by a single T cell such
that the same T cell may recognize both a foreign and self antigen 
through different TCRs, or expression of a chimeric TCR that may 
recognize either foreign or self antigens depending on its 
configuration.[62]
IgA also helps to resolve inflammation in the body, partly via clearance
of pathogens and immune complexes.[1] As discussed above, 
individuals with SIgAD have increased proclivity to infections, which 
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are likely to foster a state of chronic inflammation. The lack of IgA may 
propagate a state of lingering local and systemic inflammation. 
Lingering inflammation has a number of negative consequences for 
health, partly via the release of interferon (IFN) γ, type I IFN, 
ianterleukin (IL)-1β, IL-12, ILL-17, and tumor necrosis factor α, and may
predispose to the sensitization of immune cells to auto-antigens.
[42,49,62] 
Finally, IgA interacts with cell receptors such as FcαRI to down-regulate
immune pathways that in turn propagate inflammation.[64] This 
manifests in such downstream effects as down-regulation of neutrophil
chemotaxis.[65] In SIgAD patients, IgA is not available to carry out this 
function, and resulting lingering inflammation may predispose to 
autoimmunity, as we have discussed above.
Systemic Autoimmune Diseases
Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is a complex autoimmune disease
process whose relationship to SIgAD has been studied more thoroughly
than many of the disease entities in this review. It does appear to be 
associated with SIgAD, but it also has other known associations that 
may cause confounding. For instance, one systematic review found an 
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average SLE prevalence of 3.8% in patients with SIgAD, with 
prevalence varying based on ethnicity.[66] Prevalence was 1.5% 
among Caucasians, versus 0.8% among Chinese with SIgAD. However, 
SLE is very rarely seen in Chinese individuals, so 0.8% is a significant 
elevation in prevalence, compared to the general population. The same
review noted an association between SLE and HLA-B8, DR3, and DQ2 
in Caucasian populations. One large study examined the prevalence of 
SLE among SIgAD individuals (0.57%) and among normal controls 
(0.06%) in Sweden, and found the difference to be statistically 
significant, with a prevalence ratio of 8.9.[67] Across all studies in this 
review, prevalence of SLE among patients with SIgAD was 1.25%, 
compared to 0.24%, the highest accepted prevalence of SLE in the 
general population.[66,68-80] (Table 2) As is the case with many of the
autoimmune conditions considered here, SLE has been increasing in 
prevalence in many populations, so older studies may underestimate 
the modern prevalence of SLE in this population.[68]
Among patients with known SLE, the prevalence of SIgAD is 
approximately 2.02%, which is much higher than the prevalence of 
SIgAD observed in any healthy population.[64,67,81-84] One study 
found that these patients were significantly more likely to have anti-
Sm antibodies, anti-La antibodies, and a speckled ANA pattern than 
patients with SLE but without SIgAD.[77] These individuals did not 
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differ from their counterparts with SLE in symptoms, anti-Ro antibody 
status, or HLA. 
The existing evidence suggests an association between SIgAD and SLE,
although future studies will elucidate the role of confounding variables,
such as ethnicity and HLA types in this association.
Scleroderma/Systemic Sclerosis
Scleroderma has not been studied exhaustively in SIgAD populations, 
and has only rarely been observed. We found only four studies which 
mentioned scleroderma or systemic sclerosis. In these studies, the 
prevalence of scleroderma in SIgAD patients ranged from 0.3%-6.7%, 
with a weighted average of 0.78%, compared to a prevalence of 
0.004%-0.04% in populations with normal serum immunoglobulins.
[20,72,81,84,85] (Table 3) It is important to note that the largest of 
these studies found the lowest prevalence. This may reflect an 
observation bias, in which only studies which observed systemic 
sclerosis mentioned it, thus artificially inflating the average 
prevalence. But even the lowest observed prevalence in SIgAD 
populations is ten-fold higher than in populations without SIgAD. Thus 
the available data suggests a possible association between SIgAD and 
scleroderma which would benefit from confirmation by additional 
studies.
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Sjogren’s Syndrome
Three studies examined the prevalence of Sjogren’s Syndrome in 
SIgAD patients. Two small studies found no patients with Sjogren’s 
Syndrome.[40,82] (Table 4) A third, larger study found a single 
individual with both SIgAD and Sjogren’s Syndrome, but the difference 
in prevalence compared to a sample of the general population was not 
significant.[22] A larger study is necessary to determine whether any 
correlation exists between these diseases.
Sarcoidosis
According to two studies evaluating a total of 247 patients, the 
prevalence of sarcoidosis among individuals with SIgAD is 3.5%.[22,82]
(Table 5) The larger of the two studies found the highest prevalence, 
but did not find it to be statistically different from the prevalence in the
general population. Further studies are required to determine whether 
any association exists.
Endocrine Disorders
Thyroiditis
Rather than distinguishing between hyperthyroidism and 
hypothyroidism, many studies simply noted “thyroiditis,” which may 
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evolve into either entity, or may resolve completely. The prevalence of 
thyroiditis among patients with SIgAD ranged from 0.6% to 10.8%, with
an overall weighted average prevalence of 3.3%.
[1,14,20,40,64,81,83,86,87] (Table 6)
Hyperthyroidism
Hyperthyroidism appears to have a moderate association with SIgAD. 
The prevalence of SIgAD among patients with hyperthyroidism ranged 
from 0% to 2.7%, with a weighted average of 1.6% among five studies.
[88-92] Five studies examined the prevalence of hyperthyroidism 
among individuals with SIgAD, with estimates ranging from 0% to 
11.8%, and a weighted average of 2%.[14,22,67,82,92] (Table 7) An 
early study of 204 patients failed to find a statistically significant 
difference in prevalence between SIgAD individuals and the general 
population.[22] However, a 2011 paper found a prevalence of Graves 
disease among Swedish SIgAD individuals that was tenfold higher than 
the prevalence in the general Swedish population.[92] The largest 
study to date examined 2100 Swedish SIgAD individuals, finding a 
prevalence of hyperthyroidism of 1.7%, compared to 0.43% in the 
general Swedish population.[67] The difference was statistically 
significant with a PR of 3.9. This suggests an association between 
SIgAD and hyperthyroidism.
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Hypothyroidism
Hypothyroidism appears to have a weak association with SIgAD 
deficiency. A total of six studies have examined the prevalence of 
hypothyroidism among SIgAD individuals, finding values between 0.8%
and 4.9%, with a weighted average of 1.1%.[14,22,67,82,93,94] (Table
8) Two studies used a cohort of matched controls. The first found a 
prevalence of 1.89% and 0% in SIgAD and control populations, 
respectively, and found that the difference was statistically significant.
[22] The second study found a prevalence of 0.76% and 0.16% in 
SIgAD and control populations, respectively.[67] The difference was 
significant, with a PR of 3.9. These data support an association 
between SIgAD and hypothyroidism.
Type 1 Diabetes Mellitus
Type 1 diabetes mellitus (T1DM) is the destruction of insulin-producing 
pancreatic beta cells, typically due to autoimmunity. The incidence of 
T1DM varies by ethnicity, but it has been most extensively studied in 
Caucasians, in whom it is associated with HLA B8, DR3, and DQ2.[66] 
Among the general population, T1DM has an estimated prevalence of 
0.26% to 0.34% in the USA, versus 0.17% in Italy and 0.014% in Japan.
[95-97] T1DM appears to be associated with SIgAD, although 
25
individuals with T1DM have a similar prevalence of allergy and atopy 
when compared with the general population.[98] Compared to 0.34% - 
the highest estimated prevalence of T1DM among the general 
population of Caucasians, 11 studies have found a prevalence ranging 
from 0% to 6.35% among SIgAD individuals, with a weighted average 
of 5.12%.[1,14,20,40,66,67,81,82,87,93,94] (Table 9) Two studies 
made use of a control population. The first was a study of 330 Spanish 
individuals with SIgAD and found a prevalence of 3.03% among SIgAD 
individuals, compared to 0.08% in the general population.[20] The 
second was a study of 2100 Swedes with SIgAD, which found a 
statistically significant difference between 5.9% in the SIgAD 
population and 0.57% in the general population of Sweden, with a 
prevalence ratio of 10.[67] 
15 studies have examined the prevalence of SIgAD among individuals 
with T1DM, finding a prevalence ranging between 0% and 3.7%, with a 
weighted average of 1.06%.[66,99-111] This prevalence is higher than 
1 in 142 (0.7%), the most generous estimate of SIgAD prevalence in 
the general population. In a study of 200 Greek children, 3% of those 
with T1DM also had SIgAD, whereas the prevalence of SIgAD among 
healthy children was 0.2%.[103]
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These data support an association between T1DM and SIgAD, although 
individuals with both conditions may have fewer allergic symptoms 
than those with SIgAD alone.
Gastrointestinal Disorders
Pernicious Anemia
Pernicious anemia is an autoimmune disease process consisting of 
antibodies against intrinsic factor, its binding site in the terminal ileum,
or destruction of the parietal cells which produce it, thereby preventing
effective absorption of cobalamin.[112] Five small studies have 
examined the prevalence of this disease in the population of SIgAD 
individuals, finding a value between 0% and 2.36%, with a weighted 
average of 1.26%.[22,40,81,82,94] (Table 10) None of the five studies 
was sufficiently powered to demonstrate a correlation between 
pernicious anemia and SIgAD, and none examined the prevalence of 
SIgAD among individuals with pernicious anemia. Although the 
prevalence among SIgAD individuals is higher than the estimated 
prevalence of 0.1% in the general population, it similar to the 
estimated 1.9% prevalence among individuals over 60 years of age.
[113] Most of these studies did not elaborate on the surveillance 
method used for pernicious anemia. The observed prevalence would 
naturally be higher if all individuals were tested, as opposed to 
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symptomatic individuals only. Larger studies are necessary to 
determine whether a correlation exists between these two diseases. 
Pernicious anemia has occasionally been noted to coexist as a trifecta 
with SIgAD and celiac disease.[114] Interestingly, individuals with this 
trifecta typically lack antibodies against intrinsic factor or parietal cells,
raising suggestions that the pernicious anemia in these individuals 
may represent a distinct disease process that is unrelated to the 
classically understood pathogenesis of pernicious anemia.[115] 
The existing data are insufficient to determine whether an association 
exists between pernicious anemia and SIgAD.
Autoimmune Gastritis
Autoimmune gastritis, also known as autoimmune metaplastic atrophic
gastritis, is a broad diagnosis which is based on pathology and 
exclusion of infectious etiology, and includes the subtype of pernicious 
anemia involving antibodies against parietal cells.[116] It has an 
estimated prevalence of 2% to 5% in the general population, but these 
numbers are based on low quality studies that are likely affected by 
sampling bias.[117] Only two studies have estimated the prevalence of
this disease among SIgAD individuals, with a weighted average of 
0.51%.[20,94] (Table 11) These studies both face the same limitations 
as those dealing with pernicious anemia, above. More studies are 
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necessary to draw any conclusion about autoimmune gastritis in 
individuals with SIgAD.
Celiac Disease
Celiac Disease is an autoimmune gastrointestinal disease that results 
in gluten intolerance. It has been associated with multiple genetic loci 
and certain dietary practices, and has an estimated prevalence of 1% 
in the Western world, where it has been studied most thoroughly.[118] 
Eleven studies have examined the prevalence of SIgAD among patients
with celiac disease, finding a wide variation in prevalence from 0.55% 
to 16.67%, with a weighted average of 0.57%.[66,119-127] (Table 12) 
A recent study of 317 Americans with celiac disease found a 1.9% 
prevalence of SIgAD, and compared it to a control group, which had a 
0.4% prevalence.[125] This difference in prevalence was not deemed 
statistically significant, however the study used a more stringent 
0.03g/L cutoff, rather than the generally accepted 0.07g/L cutoff for 
diagnosing SIgAD, and may not have been sufficiently powered to 
detect a true difference in prevalence. 
Twelve studies evaluated the prevalence of celiac disease among 
individuals with SIgAD, finding values between 0.63% and 9.9%, with a
weighted average of 6.05%, which is higher than the estimated 1% 
prevalence in the general population.
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[1,14,20,22,40,64,66,67,86,93,94,128] Three of these studies 
compared the prevalence among SIgAD individuals to that found in a 
control population. The smallest of these examined 204 SIgAD 
individuals with a disease prevalence of 0.63%, compared to 0 cases in
the control population, and did not find the difference to be statistically
significant.[22] A slightly larger study of 330 SIgAD individuals found a 
prevalence of 6.67%, compared to 0.5-1.0% in control populations, and
did not mention whether the difference was significant.[20] Finally, a 
study of 2100 Swedes with SIgAD found a disease prevalence of 6.7%, 
compared with 0.19% in the control population.[67] The authors 
determined this difference to be statistically significant, with a 
prevalence ratio of 35.
Importantly, studies of celiac disease in the context of SIgAD face 
significant limitations. The first test for celiac disease is typically IgA 
antibodies against TTG, but these antibodies are rarely present in IgA 
deficient individuals.[120] Indeed, according to one study, only 9.3% of
SIgAD individuals with biopsy-confirmed celiac disease had IgG 
antibodies against TTG.[66] Therefore celiac disease in SIgAD 
individuals cannot be reliably diagnosed with the assays most widely 
used in the general population.[129] A small study suggested that 
individuals with SIgAD and celiac disease are not only more likely to 
have an additional autoimmune disease than individuals with celiac 
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disease and not SIgAD (67% vs 23.5%) but they may also have a lower 
frequency of GI symptoms (17.7% v 66.7%).[125] This has potential 
clinical significance, since asymptomatic individuals are less likely to 
be tested for celiac disease, but it is unknown whether untreated celiac
disease carries the same risk of lymphomas in these individuals. 
Studies suggest that individuals with SIgAD and celiac disease have 
statistically greater TNF-alpha and IL-10 than CD without SIgAD.[130] If
the pathogenesis of malignancy in celiac disease is associated with 
inflammatory pathways, these individuals would continue to be at risk, 
despite their relative lack of symptoms.
While the existing data suggests a likely association between SIgAD 
and Celiac Disease, more carefully designed studies are necessary to 
confirm this association. It should be noted that celiac disease cannot 
be reliably diagnosed in SIgAD individuals using IgA and IgG assays, so 
clinicians should rely on biopsies in this population. Individuals with 
SIgAD and celiac disease are also less likely to have GI symptoms, so a
higher suspicion should be maintained by clinicians caring for these 
individuals. 
Inflammatory Bowel Disease
Inflammatory bowel disease (IBD) is a category of autoimmune bowel 
disease including both ulcerative colitis and Crohn’s disease. Most 
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studies which remark on IBD treat Crohn’s disease and ulcerative 
colitis separately, but one study did not distinguish between the two 
disease entities, and another treated them both individually and also 
as IBD. These two studies found an average IBD prevalence of 3.88% 
among SIgAD individuals.[40,67] (Table 13) Ludvigsson et al. 
compared a prevalence of 3.9% among 2100 people with SIgAD to 
0.81% among controls, and found that the difference was statistically 
significant with a prevalence ratio of 5.[67] 
Crohn’s Disease
Crohn’s disease is a type of IBD that affects small and large bowel, 
often in a patchy, non-contiguous pattern. A total of six studies have 
estimated the prevalence of Crohn’s disease among SIgAD individuals, 
finding values between 1.21% and 15.8%, with a weighted average of 
2.49%.[1,20,67,84,86,94] (Table 14) One study of 330 Spaniards 
compared a prevalence of 1.21% among individuals with SIgAD with a 
prevalence of 0.13% in a control population, although the authors did 
not determine whether the difference was statistically significant.[20] 
A study of 2100 Swedes with SIgAD found the prevalence of 2.4% to be
significantly higher than 0.42% among controls, with a prevalence ratio
of 5.7.[67] These results suggest that Crohn’s disease is more 
prevalent among individuals with SIgAD.
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Ulcerative Colitis
Unlike Crohn’s disease, ulcerative colitis (UC) affects only the large 
bowel, and typically presents in a contiguous pattern. Five studies 
have examined the relationship of UC and SIgAD, finding a prevalence 
from 0.63% to 7.9%, with a weighted average of 1.73%.[1,22,67,84,87]
(Table 15) Koskinen et al. found a prevalence of 0.63% among 204 
individuals with SIgAD, which was not significantly different from the 
prevalence of 0% in the control group.[22] However, a larger study of 
2100 individuals with SIgAD found a significant difference between the 
1.7% prevalence in the SIgAD population, compared to the 0.46% 
prevalence in the control population, with a prevalence ratio of 3.9.[67]
These data suggest an association between SIgAD and UC.
Autoimmune Hepatitis
Autoimmune hepatitis (AIH), is an inflammatory condition with unclear 
pathogenesis involving T-cells targeting the liver. Although precise 
antigens have yet to be identified for many forms of AIH, confirmed 
subtypes include anti-LKM1, which targets CYP2D6, anti-soluble liver 
antigen/liver pancrease, which targets SEPSECS, and anti-LC1, which 
targets formiminotransferase cyclodeaminase.[131] Other variants of 
the disease are associated with the nonspecific antinuclear antibody 
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(ANA) or anti-smooth muscle antibody (SMA), and still others have not 
yet been associated with any known autoantibody.[131] The 
prevalence of this disease varies based on gender, ethnicity, and age, 
but it is estimated at 0.005% in South Korea, 0.024% in Denmark, and 
0.023% in Japan, and appears in a female predominant pattern.[132-
134]
Three studies have examined the prevalence of SIgAD among patients 
with AIH, finding a weighted average of 4.75%[135-137] (Table 16) 
However, one study of anti-LKM1 positive AIH involved only 5 patients 
and reported a 40% prevalence.[135] Removing this study from the 
weighted average yields a 2.87% prevalence rate. The significance of 
this result is uncertain due to the small sample size of the study, 
however a larger study of pediatric patients found that the prevalence 
of partial IgA deficiency (defined as 1.20g/L or less) was 45% in anti-
LKM1 positive AIJ, versus 9% in ANA/SMA positive AIH.[136] An 
additional study of 65 French adults with anti-LKM1 positive AIH 
reported that 29% has low (defined as 1.2g/L or less), and 4.6% had 
undetectable (did not report a specified cutoff) serum IgA.[137] More 
studies are warranted to determine whether any connection exists 
between SIgAD and the specific subtypes of AIH.
Five studies reported the prevalence of AIH among patients with AIH, 
with a range of 0.79% to 5%, and a weighted average of 1.57%.
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[20,24,40,81,83] None of these five studies used a control group, so 
the significance of these results cannot be determined.
The existing data suggests a likely association with AIH, specifically the
anti-LKM1 positive subtype. However, larger studies are required to 
confirm this association.
Primary Sclerosing Cholangitis
Primary Sclerosing Cholangitis (PSC) is an idiopathic condition involving
inflammation and destruction of the bile ducts, with a prevalence in 
North America and Europe of 0.006% to 0.016%.[138] Only a single 
study reported prevalence of PSC among individuals with SIgAD, 
finding a value of 0.79% among 126 Brazilians.[64] This value is higher
than the estimated prevalence in the general population of North 
America, but these numbers represent different populations, and 
cannot be directly compared. No general prevalence data was found 
for Brazil, so further studies are needed to determine whether an 
association exists.
Musculoskeletal Disorders
Rheumatoid Arthritis
Rheumatoid arthritis (RA) is an autoimmune disease characterized 
primarily by synovial inflammation and joint destruction, and 
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classically characterized by rheumatoid factor and anti-cyclic 
citrullinated peptide antibodies. It has an estimated prevalence of 
0.41% to 0.54% among insured adults in the USA.[139]
Five studies have examined the prevalence of SIgAD among individuals
with RA, finding a range of 0.25% to 4%, with a weighted average of 
0.5%.[71,75,140-142] Seven studies reported the prevalence of RA 
among individuals with SIgAD, finding a range of 2.2% to 5.7%, and a 
weighted average of 2.4%.[22,24,67,81-84] (Table 17) Two of these 
studies used control groups. Koskinen et al found no individuals with 
RA in the control group, and did not determine the significance of the 
prevalence discrepancy.[22] Ludvigsson et al found a prevalence of 
2.2% for RA among those with SIgAD versus 0.5% in the control group, 
which is consistent with other prevalence estimates for RA in the 
general population.[67] The authors determined that the difference in 
prevalence was statistically significant, with a prevalence ratio of 4.5. 
Individuals with both RA and SIgAD did not differ in terms of long term 
disease activity or mortality compared to those with RA alone.[140]
The available data support an association between RA and SIgAD.
Juvenile Idiopathic Arthritis
Juvenile idiopathic arthritis (JIA) is a chronic arthritis affecting children, 
with a general prevalence between 0.0038% and 0.4%.[143] Nine 
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studies have examined the prevalence of SIgAD among children with 
JIA, finding a range from 1% to 4.35%, with a weighted average of 
2.7%.[79,144-151] (Table 18) A total of nine studies reported the 
prevalence of JIA among individuals with SIgAD, finding 0% to 15.67%, 
with a weighted average of 1.97%.[1,20,39,67,72,81,83,86,93] Two of 
these studies utilized control groups. One study found that 3.33% of 
patients with SIgAD, and only 0.11% of the general population had JIA, 
but the significance of this difference was not reported.[20] The other 
study showed that 0.76% of patients with known SIgAD had JIA, 
compared to 0.09% of controls, for a prevalence ratio of 8.9, and the 
authors determined this to be a statistically significant difference.[67] 
These data support an association between JIA and SIgAD.
Ankylosing Spondylitis
The prevalence of ankylosing spondylitis (AS) has been estimated as 
ranging from a high of 0.238% in Europe to a low of 0.074 in Africa.
[152] Only four studies have reported the prevalence of AS among 
individuals with SIgAD, finding a range of 0% to 2.52%, with a 
weighted average of 1.73%.[14,22,82,83] (Table 19) The largest of 
these studies involved only 204 individuals with SIgAD, however it 
compared the 2.52% prevalence in this group to a control group, in 
which the prevalence was 0.42%.[22] This difference was not found to 
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be statistically significant, possibly because the study was not 
sufficiently powered.
This disease appears to manifest differently, depending on the HLA 
type of the affected individual. Serum levels of IgA are negatively 
associated with disease activity in HLA-B27 negative individuals, but 
not in B27 positive patients.[153] It has additionally been suggested 
that SIgAD is a poor prognostic marker for AS.[154]
Limited evidence suggests that an association may exist between 
SIgAD and AS – particularly in HLA-B27 negative individuals – but more 
studies are necessary to elucidate this connection.
Myositis
Myositis refers to a broad spectrum of disease processes, whose 
breadth makes it difficult to determine the overall prevalence in the 
general population. However, most studies of SIgAD populations do not
distinguish between individual etiologies of myositis when reporting 
prevalence. Five studies report the prevalence of myositis in 
populations with SIgAD, ranging from 0% to 7.32%, with a weighted 
average of 3.58%.[1,40,72,83,155] (Table 20) No studies reported the 
prevalence of SIgAD among patients with myositis, although one study 
observed that IgA levels in people with polymyositis and 
dermatomyositis were similar to those in controls.[155] The existing 
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data is inadequate to determine whether any relationship exists 
between SIgAD and myositis.
Dermatologic Disorders
Vitiligo
Vitiligo is an autoimmune disorder resulting in the destruction of 
melanocytes in a patchy distribution, and is estimated to have a global
prevalence of approximately 1%.[156] Only a single study reported the
prevalence of SIgAD among individuals with vitiligo, finding a 
prevalence of 50% in the SIgAD population, which was significantly 
higher than a prevalence of 36.7% among controls.[157] It should be 
noted that the cutoff used for SIgAD in this study was very high at 4 
g/L, so the study likely overestimates the prevalence of SIgAD in both 
groups. A larger study found no significant difference in IgA levels 
between individuals with and without vitiligo, but it was not designed 
to detect SIgAD.[158]
Nine studies investigated the prevalence of vitiligo among patients 
with SIgAD, with results varying between 0.79% and 15.38%, with a 
weighted average of 2.89%.[1,20,22,28,40,64,86,87,94] (Table 21) 
Only one of these studies used a control group, finding a prevalence of 
4.4% and 0.42% among patients with SIgAD and controls, respectively,
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and found the difference to be significant.[22] These results suggest a 
relationship between vitiligo and SIgAD.
Psoriasis
Psoriasis is an inflammatory skin disease that is associated with 
arthritis in some individuals. It has a prevalence between 0.73% and 
3.2%, with prevalence increasing with greater distance from the 
equator, and in adults, compared to children.[159-161] Psoriasis has 
been associated with multiple sclerosis, metabolic syndrome, 
inflammatory bowel disease, and psychiatric disease, although no 
studies have reported on the prevalence of SIgAD among individuals 
with psoriasis.[162-165] Seven studies have reported the prevalence of
psoriasis among individuals with SIgAD, with results varying between 
0% and 6.3%, with a weighted average of 2.72%.
[22,23,28,40,82,93,94] (Table 22) Each of these studies was relatively 
small, and although two used control populations, neither was 
sufficiently powered to detect a difference between the populations.
[22,23] Studies of psoriasis patients have shown high and low levels of 
IgA, and it has been postulated that IgA may be involved in the 
pathogenesis of persistent stationary psoriasis, while acting as a 
protective factor against guttate-type psoriasis.[166] It has been 
suggested that IgA impairs neutrophil chemotaxis, which would 
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support this observation.[65] Unfortunately, none of the studies of 
psoriasis in individuals with SIgAD reliably distinguish between 
subtypes of psoriasis. Larger studies are necessary to elucidate any 
such relationship with specific subtypes of psoriasis.
Alopecia Areata
Alopecia areata is an autoimmune condition resulting in destruction of 
hair follicles, resulting in nonscarring hair loss. It has a reported 
prevalence in the United States of 0.1% to 0.2%.[167] No studies were 
found to report the prevalence of SIgAD among individuals with 
alopecia areata, but four studies have reported the prevalence of 
alopecia areata within SIgAD populations, varying from 0.9% to 3.51%, 
with a weighted average of 2.3%.[1,28,40,86] (Table 23) All of these 
studies were small, with the largest only involving 102 participants. No 
study used a control group. While all four studies found a prevalence 
higher than would be expected in the general population, it is 
impossible to determine whether any true association exists, based on 
the current data.
Recurrent Aphthous Stomatitis
Recurrent aphthous stomatitis (RAS) is an inflammatory condition 
resulting in painful ulcerations on the oropharyngeal mucosa, and is 
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thought to affect approximately 1.6% of the general population.[168] 
Three studies reported prevalence of RAS among individuals with 
SIgAD, finding values from 1.2% to 4.9%, with a weighted average of 
2.4%.[20,28,128] (Table 24) However, RAS is associated with other 
autoimmune disorders including Celiac disease and inflammatory 
bowel disease, and may be a manifestation of these diseases in some 
cases.[168] Without controlling for these disease entities, it is 
impossible to determine whether RAS has a separate correlation with 
SIgAD.
Lichen Planus
Lichen planus is a disease affecting the stratified squamous epithelia 
with uncertain etiology, and with a prevalence ranging 0.22% to 5%.
[169] The prevalence of lichen planus among individuals with SIgAD 
has only been recorded by two studies, with a weighted average of 
0.97%.[22,40] (Table 25) Koskinen et al. used a control group, and 
although the prevalence was higher among the SIgAD group, the 
difference was not significant. The limited available data does not 
suggest that the prevalence of lichen planus in SIgAD individuals 
differs from that of the general population.
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Renal
Glomerulonephritis
Glomerulonephritis denotes inflammation of the glomerulus, which 
may occur secondary to multiple primary and secondary etiologies. 
Observed prevalence varies between 0.12% and 1.23%, depending on 
the population.[170] 
A single study noted the prevalence of SIgAD among individuals with 
glomerulonephritis as 0.7%, compared to 0% of a healthy control 
group, and this difference was not statistically significant.[80] 
Two studies reported the prevalence of glomerulonephritis in SIgAD 
populations, finding a weighted average of 1.49%.[22,24] (Table 26) 
The larger of the two studies compared the results to a control 
populations, and did not find a significant difference in prevalence.[22] 
The existing data is very limited, but it does not support a relationship 
between SIgAD and glomerulonephritis.
Neuromuscular Disorders
Myasthenia Gravis
Myasthenia Gravis (MG) is a neuromuscular disorder in which 
antibodies form against the post-synaptic acetylcholine receptor, 
inhibiting signaling at the neuromuscular junction. It has an estimated 
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prevalence of 0.08% in the general population, with greater prevalence
among older populations.[171] 
Seven studies have reported the prevalence of SIgAD among 
individuals with MG, ranging from 0% to 1.85%, with a weighted 
average of 0.44%.[66,155,172-176] (Table 27) The most recent of 
these papers used a control group, and found no significant difference 
in prevalence.[176] 
Five studies examined the prevalence of MG among SIgAD populations,
finding a rate of 0% to 2.7%, with a weighted average of 0.18%.
[1,40,67,86,155] The largest of these studies used a control group, 
finding no significant difference in prevalence.[67] The existing 
evidence does not support a correlation between SIgAD and MG.
Multiple Sclerosis
There have been two case reports of Multiple Sclerosis (MS) in patients 
with SIgAD, raising the possibility of a correlation.[177,178] However, 
two small studies have failed to find any cases of MS among patients 
with SIgAD.[40,82] Moreover, any association between MS and SIgAD is
unlikely to be missed, because the diagnostic workup for MS typically 
includes CSF immunoglobulins, which would likely reveal any 
previously undiagnosed SIgAD.[179] There is therefore no evidence to 
support a correlation between MS and SIgAD.
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Hematologic Disorders
Immune Thrombocytopenic Purpura
Immune Thrombocytopenic Purpura (ITP) is an autoimmune disorder 
resulting in the destruction of platelets. Good quality studies of 
prevalence are lacking, it has been estimated at 0.024% in the general
population in the US.[180] It is widely assumed to be one of the most 
prevalent autoimmune manifestations of SIgAD. Multiple reviews report
a prevalence of 1:200, citing the same article, which does not supply 
data about ITP.[181] Seven studies have reported on the prevalence of
ITP among individuals with SIgAD, varying from 0% to 5.71%, with a 
weighted average of 1.8%.[20,24,39,40,81,82,93] (Table 28) None of 
these studies utilized control groups, so although the reported 
prevalence is greater among SIgAD populations, it is impossible to 
determine whether this difference is statistically significant.
Autoimmune Hemolytic Anemia
Autoimmune Hemolytic Anemia (AIHA) is the activation of the immune 
system against red blood cells, causing their lysis. Because it 
encompasses multiple etiologies, there is little good quality data on 
prevalence in the general population. However, prevalence has been 
estimated at 0.017%.[182]
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Only a single study examined the prevalence of SIgAD among 
individuals with AIHA, finding a prevalence of 17%.[183] Rather than 
using the accepted definition of SIgAD, this study defined it as a value 
2 standard deviations below the mean, which limits the applicability of 
the results.
Eight studies reported the prevalence of AIHA among individuals with 
SIgAD, reporting values between 0% and 15.38%, yielding a weighted 
average of 2.18%.[1,20,39,40,64,81,86,87] (Table 29) The small size of
the studies, the wide variability of the results, and the lack of control 
groups make it difficult to draw conclusions from these findings. 
However, it is interesting to note that on average, French children with 
isolated AIHA (not associated with Evans syndrome) had lower-than-
average IgA levels.[183] 
Although the existing data suggest a possible relationship between 
SIgAD and AIHA, it cannot be confirmed without additional studies.
Insufficient Data
Multiple additional conditions have been noted in SIgAD individuals 
only in single studies, with insufficient data to compare prevalence to 
that of the general population. These included autoimmune 
lymphoproliferative syndrome[1], uveitis[20], rheumatic fever[22], 
Guillain-barre[40], Stills disease[71], pemphigus vulgaris[82], Stevens-
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Johnson[82], interstitial systitis[82], polymyalgia rheumatica[82], 
reactive arthritis[82], cryoglobulinemia[81], vasculitis[81], Henoch 
Schonlein Purpura[22], Kawasaki disease[40], anti-sperm 
antibodies[81], granuloma annulare[93], familial mediterannean 
fever[14], and pulmonary hemosiderosis[14]. The available data can 
be found in the appendices.
No prevalence data could be found regarding mixed connective tissue 
disease, hidradenitis suppurativa, primary biliary cirrhosis, or bullous 
pemphigoid.
Discussion
The data presented in this review makes it clear that in addition to 
other clinically important manifestations of SIgAD, this disease is also 
associated with a number of autoimmune diseases. Between one 
quarter and one third of individuals with SIgAD are afflicted with 
autoimmune disease, but SIgAD does not guarantee the development 
of such a condition.[1,40,41] Clinicians should keep this association in 
mind, maintaining a high level of suspicion for autoimmune disease in 
patients with known SIgAD, and in some cases screening for Systemic 
Lupus Erythematosus, hyperthyroidism, hypothyroidism, type 1 
diabetes mellitus, Crohn’s Disease, ulcerative colitis, rheumatoid 
arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, and vitiligo
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– the autoimmune entities with the strongest association with SIgAD. 
Clinicians should also be aware that the current 0.07g/L cutoff for 
diagnosing SIgAD is somewhat arbitrary. It remains unclear whether 
patients with IgA levels near, but not below this level carry a similarly 
increased risk for developing autoimmune disease. There is some 
evidence that SIgAD may be stratified into variants that do or do not 
carry an increased risk for autoimmune disease, based, for instance on
the existence of a class switching defect, which may favor autoimmune
manifestations.[1] Nevertheless, further studies are necessary to 
elucidate the clinical utility of assessing complement profiles, IgG 
subtypes, class switching defects, or monogenic variants in patients 
with SIgAD. We hope that further research in this area will reveal 
interventions for preventing the development of autoimmunity in 
people with selective IgA deficiency.
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Figure Legend
Fig 1 depicts the structure of IgA in its monomeric form (left) and 
dimeric form (right). While both forms are found in secretions and 
serum, the monomeric form predominates in serum, while the dimeric 
form predominates in secretions. The monomeric form is composed of 
an Fc region made of two heavy chains attached via disulfide bonds in 
the hinge region to the antigen binding fragment (Fab), which is made 
up of two arms composed of one heavy chain and one light chain each.
The Fc region has a constant structure across all IgA molecules, and 
allows IgA to interact with immune cells via the IgA receptor. The tip of 
each Fab arm contains a hypervariable region which is specifically 
designed to bind a particular antigen. The dimeric IgA form consists of 
two monomeric IgA molecules linked end to end by a J-chain at the Fc 
regions, and wrapped with the secretory component, which is a protein
that inhibits digestion of the IgA by proteases.
Figure 1
TABLES
Table 1: Putative Mechanisms of Autoimmunity in SIgAD 
Mode of 
Autoimmuni
ty
Mechanism Evidence
Human 
Leukocyte 
Antigen 
(HLA) 
HLA genes that favor the 
development of SIgAD also
predispose individuals to 
autoimmunity.
 45% of IgAD patients have haplotype 8.1 (HLA-A1, B8, 
DR3, DQ2), versus 16% in general population. HLA-DR7, 
DQ2 and HLA-DR1, DQ5 are also common.[13,44-47]
 Familial clustering of SIgAD.[43]
 Several HLA variants are common in SIgAD and 
autoimmune disease.[49]
Cytogenetic SIgAD involves B cell, T 
cell, or cytokine 
abnormalities which 
predispose to 
autoimmunity.
 T regulatory cell deficiency in 64% of known SIgAD 
patients, and was significantly associated with 
autoimmunity.[40]
 Lower numbers of CD4+ lymphocytes and switched 
memory B cells.[52]
 SIgAD patients with fewer switched memory B cells were 
more prone to infection and autoimmunity.[53]
 Over one quarter of individuals with SIgAD also have low 
levels of IgG3 or IgG4, suggesting possible subclinical B 
cell abnormalities.[54]
 Increase in IgA production in SIgAD patients after 
stimulation with certain cytokines, arguing for the 
existence of a class-switching defect.[56,57]
 Presence of immature IgA positive B cells in SIgAD 
patients suggests a B cell maturation defect.[58]
 SIgAD can be transferred by bone marrow grafting.[46]
Monogenic Certain genetic mutations 
associated with SIgAD and 
other primary 
immunodeficiency (PID) 
 Patients with known PID gene mutations are more likely to
have symptomatic autoimmunity than the general 
population of individuals with SIgAD.[10]
 There is an association between certain monogenic 
syndromes predispose 
patients to developing 
autoimmunity.
mutations (CTLA4-ICOS, TACI) and autoimmunity.
[58,60,61]
Molecular 
Mimicry
Without IgA to protect 
mucosal barriers, 
pathogens enter the body 
more frequently. With 
increased exposure to 
pathogens, B and T cells 
are more likely to become 
sensitized to antigens that 
cause them to cross-react 
with self-antigens.
 Increased infection rates among SIgAD patients.
[1,20,22,23]
 Increased atopy rate suggests increased exposure of 
immune system to foreign antigens, and possibly more 
porous mucosal barriers.[1,14,20,24,27,28]
Lingering 
Inflammatio
n and 
Immune 
Complexes
SIgAD interferes with the 
resolution of inflammation 
and the clearance of 
immune complexes. Thus 
the immune system is 
more likely to become 
sensitized to auto-
antigens.
 IgA is known to have a role in resolution of inflammation 
and clearance of pathogens and immune complexes.
[1,42,49]
Dysregulati
on of 
Molecular 
Pathways
IgA directly interacts with 
cell receptors to down-
regulate immune 
pathways and protect 
against autoimmunity. Low
IgA states prevent this.
 The interaction of IgA with FcαRI receptor leads to partial 
phosphorylation of FCRγ1-associated FcαRI, deactivating 
certain immune pathways.[64]
 IgA down-regulates neutrophil chemotaxis.[65]
Table 2: SLE in SIgAD
Year Referenc
e
Count
ry
Sampl
e Size
SIgAD
Prevalenc
e among
SLE (%)
Disease
Prevalence
among
SIgAD (%)
1969 [71] USA 87 4.6
1972 [69] Mexico 106 0.94
1976 [73] USA 114 2.63
1979 [83] USA 83 12.05
1983 [80] UK 138 2.9a
1985 [75] Turkey 96 3.13
1988 [78] France 72 4.17
1990 [70] Spain 130 0.77
1991 [74] USA 31 9.7
1997 [77] UK 96 5.21
2004 [81] USA 127 2.36
2005 [84] Puerto
Rico
38 13.2
2007 [72] USA 77 5.19
2007 [72] USA 152 5.26
2008 [64] Brazil 126 0.79
2009 [82] Iceland 43 0
2010 [76] Brazil 189 5.82b
2011 [66] Swede
n
706 1.56
2011 [66] UK 844 0.59
2011 [66] USA 874 2.29
2011 [66] China 964 0.83
2014 [67] Swede
n
2100 0.57c
2015 [79] Roman
ia
21 4.76  
Weigh
ted
Avera
ge
2.02 1.25
a0% prevalence among control group
bReported as statistically significant
c0.06% prevalence among control group, reaching statistical significance 
with a PR of 8.9
Table 3: Scleroderma and SIgAD
Year Referen
ce
Countr
y
Sampl
e Size
Disease
Prevalence
among SIgAD
(%)
2004 [81] USA 127 0.79
2005 [84] Puerto
Rico
38 2.6
2007 [72] USA 15 6.67
2012 [20] Spain 330 0.3
Weigh
ted
Averag
e
0.78
Table 4: Sjogren’s Syndrome and SIgAD
Year Refere
nce
Count
ry
Sampl
e Size
Disease
Prevalence
among SIgAD
(%)
1996 [22] NM 204 0.63a
2009 [82] Icelan
d
43 0
2017 [40] Iran 60 0
Weigh
ted
Averag
e
0.42
a0% prevalence among control group; not statistically significant
Table 5: Sarcoidosis and SIgAD
Year Refere
nce
Count
ry
Sampl
e Size
Disease
Prevalence
among SIgAD
(%)
1996 [22] NM 204 3.77a
2009 [82] Icelan
d
43 2.33
Weigh
ted
Averag
e
3.52
a1.27% prevalence among controls, but did not reach statistical significance
Table 6: Thyroiditis and SIgAD
Year Reference Count
ry
Sampl
e Size
Disease
Prevalence
among
SIgAD (%)
1979 [83] USA 83 2.41
2004 [81] USA 127 2.36
2008 [64] Brazil 126 7.14
2009 [86] Iran 37 10.81
2012 [20] Spain 330 0.61
2013 [87] Iran 26 3.85
2015 [1] Iran 57 5.26
2017 [40] Iran 60 8.3
2017 [14] Turkey 81 2.5
Weigh
ted
Averag
e
3.35
Table 7: Hyperthyroidism and SIgAD
Year Refere
nce
Count
ry
Sampl
e Size
SIgAD
Prevalence
among
Hyperthyro
idism (%)
Disease
Prevalence
among SIgAD
(%)
1994 [90] Finlan
d
52 0
1996 [22] NM 204 0.63
1999 [91] Italy 23 0
1999 [88] Italy 18 0
2005 [89] UK 111 2.7
2009 [82] Icelan
d
43 0
2011 [92] Swede
n
841 1.66 11.8a
2014 [67] Swede
n
2100 1.7b
2017 [14] Turkey 81  3.7
Weigh
ted
Avera
ge
1.62 2.02
an=93 for “disease prevalence among SIgAD.”
b0.43% prevalence among controls, and reached statistical significance with 
a PR of 3.9
Table 8: Hypothyroidism and SIgAD
Year Refere
nce
Count
ry
Sampl
e Size
Disease
Prevalence
among SIgAD
(%)
1996 [22] NM 204 1.89a
2009 [82] Icelan
d
43 2.33
2010 [94] Israel 63 3.17
2012 [93] Turkey 118 0.8
2014 [67] Swede
n
2100 0.76b
2017 [14] Turkey 81 4.94
Weigh
ted
Averag
e
1.06
a0% prevalence among controls, and reported as statistically significant
b0.16% prevalence among controls, and reported as statistically significant with a 
PR 4.6
Table 9: Type 1 Diabetes and SIgAD
Year Referenc
e
Count
ry
Sampl
e Size
SIgAD
Prevalenc
e among
T1DM (%)
Disease
Prevalence
among
SIgAD (%)
1978 [111] USA 421 0
366 2.46
1982 [104] Canad
a
129 1.55
1983 [100] Germa
ny
483 2.9
1988 [101] Italy 191 3.66
1992 [106] USA 261 0.38
1994 [107] UK 1785 0.45
1998 [99] UK 167 1.8
1998 [102] Canad
a
236 0
2000 [110] Austria 403 0.5
2004 [81] USA 127 1.57
2005 [108] Italy 94 0
2006 [105] Tunisia 261 1.92
2009 [82] Iceland 43 0
2012 [109] Iran 300 0.67
2010 [94] Israel 63 6.35
2011 [66] Swede
n
1252 0.88 2.8a
2011 [66] Italy 245 0.82
2012 [20] Spain 330 3.03b
2012 [93] Turkey 118 5.9
2013 [87] Iran 26 3.85
2014 [67] Swede
n
2100 5.9c
2015 [1] Iran 57 3.51
2016 [14] Turkey 81 3.7
2017 [40] Iran 60 1.7
2016 [103] Greece 200 3  
Weigh
ted
Avera
ge
1.06 5.12
an not provided for “disease prevalence among SIgAD,” so value was not 
included in weighted average
b0.08% prevalence among controls; statistical significance not reported
c0.57% prevalence among controls, and reached statistical significance with 
PR 10
Table 10: Pernicious Anemia and SIgAD
Year Refere
nce
Count
ry
Sampl
e Size
Disease
Prevalence
among SIgAD
(%)
1996 [22] NM 204 0.63a
2004 [81] USA 127 2.36
2009 [82] Icelan
d
43 2.33
2010 [94] Israel 63 1.59
2017 [40] Iran 60 0
Weigh
ted
Averag
e
1.26
a0% prevalence among controls; difference did not reach statistical significance
Table 11: Autoimmune Gastritis and SIgAD
Year Referen
ce
Count
ry
Sampl
e Size
Disease
Prevalence
among SIgAD
(%)
2010 [94] Israel 63 1.59
2012 [20] Spain 330 0.3
Weigh
ted
Averag
e
0.51
Table 12: Celiac Disease and SIgAD
Year Reference Count
ry
Sampl
e Size
SIgAD
Prevalen
ce among
Celiac
Disease
(%)
Disease
Prevalence
among
SIgAD (%)
1992 [123] Swede
n
24 16.67
1996 [128] Italy 65 7.7
1996 [22] NM 204 0.63a
1997 [119] Italy 688 1.74b
1997 [122] Ireland 604 2.32
1998 [120] Italy 1776 2.59
322 2.48
2000 [121] Turkey 104 2.88
2000 [126] Spain 47 10.64
2006 [127] UK 4698 0.75
2008 [124] Canad
a
608 0.66
2008 [64] Brazil 126 3.97
2009 [86] Iran 37 2.7
2010 [94] Israel 63 3.17
2011 [66] Swede
n
422225 0.55 7.7-8.7c
2012 [20] Spain 330 6.67d
2012 [93] Turkey 118 5.9
2014 [67] Swede
n
2100 6.7e
2015 [1] Iran 57 3.51
2017 [14] Turkey 81 9.9
2016 [125] USA 317 1.9f
2017 [40] Iran 60  3.3
Weigh
ted
Avera
ge
0.57 6.05
a0% prevalence among controls, but did not reach statistical significance
bauthors did not utilize a control group, but reported a PR 15.8
cn not provided, so not included in total
dauthors reported prevalence among controls as 0.5-1%
e0.19% prevalence among controls, which reached statistical significance with a PR 
of 35
f0.4% prevalence among controls, but did not reach statistical significance
Table 13: Inflammatory Bowel Disease and SIgAD
Year Refere
nce
Count
ry
Sampl
e Size
Disease
Prevalence
among SIgAD
(%)
2014 [67] Swede
n
2100 3.9a
2017 [40] Iran 60 3.3
Weigh
ted
Averag
e
3.88
a0.81% prevalence among controls, reaching statistical significance with a PR of 5
Table 14: Crohn’s Disease and SIgAD
Year Reference Count
ry
Sampl
e Size
Disease
Prevalence
among
SIgAD (%)
2005 [84] Puerto
Rico
38 15.8
2009 [86] Iran 37 2.7
2010 [94] Israel 63 4.76
2012 [20] Spain 330 1.21a
2014 [67] Swede
n
2100 2.4b
2015 [1] Iran 57 1.75
Weigh
ted
Avera
ge
2.49
a0.13% prevalence among controls, but authors did not report statistical 
significance
b0.42% prevalence among controls, reaching statistical significance with a PR of 5.7
Table 15: Ulcerative Colitis and SIgAD
Year Referen
ce
Count
ry
Sampl
e Size
Disease
Prevalence
among SIgAD
(%)
1996 [22] NM 204 0.63a
2005 [84] Puerto
Rico
38 7.9
2013 [87] Iran 26 3.85
2014 [67] Swede
n
2100 1.7b
2015 [1] Iran 57 1.75
Weigh
ted
Avera
ge
1.73
a0% prevalence among controls, but did not reach statistical significance
b0.46% prevalence among controls, reaching statistical significance with a PR of 3.9
Table 16: Autoimmune Hepatitis and SIgAD
Year Refere
nce
Count
ry
Sampl
e Size
SIgAD
Prevalence
among
Autoimmu
ne
Hepatitis
(%)
Disease
Prevalence
among SIgAD
(%)
1979 [83] USA 83 1.2
1980 [24] Italy 35 2.86
1987 [137] France 42 3.57
1997 [136] UK 52 2.31
2000 [135] USA 5 40
2004 [81] USA 127 0.79
2012 [20] Spain 330 1.21
2017 [40] Iran 60  5
Weigh
ted
Avera
ge
4.75 1.57
Table 17: Rheumatoid Arthritis and SIgAD
Year Refere
nce
Count
ry
Sampl
e Size
SIgAD
Prevalence
among RA
(%)
Disease
Prevalence
among SIgAD
(%)
1969 [71] USA 61 1.64
1971 [141] Norwa
y
3187 0.25
1979 [83] USA 83 4.82
1980 [24] Italy 35 5.71
1985 [75] Turkey 25 4
1996 [22] NM 204 2.52a
1997 [142] India 69 1.45
2003 [140] UK 352 2.27
2004 [81] USA 127 2.36
2005 [84] Puerto
Rico
38 5.3
2009 [82] Iceland 43 4.65
2014 [67] Swede
n
2100  2.2b
Weigh
ted
Avera
ge
0.51 2.45
a0% prevalence among controls; statistical significance was not reported
b0.5% prevalence among controls, reaching statistical significance with a PR of 4.5
Table 18: Juvenile Idiopathic Arthritis and SIgAD
Year Reference Count
ry
Sampl
e Size
SIgAD
Prevalen
ce
among
JIA (%)
Disease
Prevalence
among
SIgAD (%)
1970 [145] USA 200 1
1972 [149] USA 176 1.7
1973 [151] Finlan
d
115 4.35
1973 [146] USA 200 4
1977 [147] USA 324 4.32
1979 [83] USA 83 15.67
1979 [144] UK 582 2.06
1983 [150] Finlan
d
350 2.86
2004 [81] USA 127 3.15
2007 [72] USA 477 3.77
2009 [86] Iran 37 2.7
2011 [148] Iran 83 1.2
2012 [20] Spain 330 3.33a
2012 [93] Turkey 118 1.6
2014 [67] Swede
n
2100 0.76b
2015 [79] Roman
ia
84 2.38
2015 [1] Iran 57 3.51
2015 [39] Iran 63  0
 Weight
ed
Averag
e
   2.7 1.97
a0.11% prevalence among controls; statistical significance was not reported
b0.09% prevalence among controls, reaching statistical significance with a PR of 8.9
Table 19: Ankylosing Spondylitis and SIgAD
Year Refere
nce
Count
ry
Sampl
e Size
Disease
Prevalence
among SIgAD
(%)
1979 [83] USA 83 1.2
1996 [22] NM 204 2.52a
2009 [82] Icelan
d
43 0
2017 [14] Turkey 81 1.2
Weigh
ted
Averag
e 
   1.73
a0.42% prevalence among controls, but did not reach statistical significance
Table 20: Myositis and SIgAD
Year Referen
ce
Count
ry
Sampl
e Size
Disease
Prevalence
among SIgAD
(%)
1976 [155] USA 11 0
1979 [83] USA 83 3.61
2007 [72] USA 41 7.32
2015 [1] Iran 57 3.51
2017 [40] Iran 60 1.7
Weigh
ted
Avera
ge
3.58
Table 21: Vitiligo and SIgAD
Year Reference Countr
y
Sampl
e Size
SIgAD
Prevalen
ce
among
Vitiligo
(%)
Disease
Prevalenc
e among
SIgAD (%)
1996 [22] NM 204 4.4a
2008 [64] Brazil 126 0.79
2009 [86] Iran 37 2.7
2010 [94] Israel 63 1.59
2010 [157] Banglad
esh
30 50b
2012 [20] Spain 330 1.21
2013 [87] Iran 26 15.38
2015 [1] Iran 57 5.26
2015 [28] Italy 102 3.06
2017 [40] Iran 60  5
Weigh
ted
Avera
ge
2.89
a0.42% prevalence among controls, reaching statistical significance
b36.67% prevalence among controls, reaching statistical significance
Table 22: Psoriasis and SIgAD
Year Refere
nce
Count
ry
Sampl
e Size
Disease
Prevalence
among SIgAD
(%)
1996 [22] NM 204 4.4a
2009 [82] Icelan
d
43 4.65
2010 [94] Israel 63 1.59
2012 [93] Turkey 118 0.8
2013 [23] Icelan
d
32 6.3b
2015 [28] Italy 102 1.96
2017 [40] Iran 60 0
Weigh
ted
Averag
e
2.72
a1.69% prevalence among controls, which did not reach statistical significance
b0% prevalence among controls, which did not reach statistical significance
Table 23: Alopecia and SIgAD
Year Reference Count
ry
Sampl
e Size
Disease
Prevalence
among
SIgAD (%)
2009 [86] Iran 37 2.7
2015 [1] Iran 57 3.51
2015 [28] Italy 102 0.9
2017 [40] Iran 60 3.3
Weigh
ted
Avera
ge
2.30
Table 24: Recurrent Aphthous Stomatitis and SIgAD
Year Referen
ce
Count
ry
Sampl
e Size
Disease
Prevalence
among SIgAD
(%)
1996 [128] Italy 65 4.6
2012 [20] Spain 330 1.2
2015 [28] Italy 102 4.9
Weigh
ted
Averag
e
2.40
Table 25: Lichen Planus and SIgAD
Year Refere
nce
Count
ry
Sampl
e Size
Disease
Prevalence
among SIgAD
(%)
1996 [22] NM 204 1.26a
2017 [40] Iran 60 0
Weigh
ted
Avera
ge
0.97
a0% prevalence among controls, which did not reach statistical significance
Table 26: Glomerulonephritis and SIgAD
Year Refere
nce
Count
ry
Sampl
e Size
SIgAD
Prevalence
among
Glomerulone
phritis (%)
Disease
Prevalence
among SIgAD
(%)
1980 [24] Italy 35 2.86
1983 [80] UK 143 0.7a
1996 [22] NM 204  1.26a
Weigh
ted
Avera
ge
1.49
a0% prevalence among controls; statistical significance was not reported
Table 27: Myasthenia Gravis and SIgAD
Year Reference Count
ry
Sampl
e Size
SIgAD
Prevalen
ce among
MG (%)
Disease
Prevalence
among
SIgAD (%)
1972 [174] UK 54 1.85
1976 [172] UK 51 3
1976 [155] USA 19 0
1976 [155] USA 51 0
1976 [173] USA 107 0
1992 [184] France 333 0.3a
2009 [86] Iran 37 2.7
2011 [66] Swede
n
512 0.3
2011 [176] Swede
n
482 0.41b
2014 [67] Swede
n
2100 0.05c
2015 [1] Iran 57 1.75
2017 [40] Iran 60  1.7
Weigh
ted
Avera
ge
0.44 1.18
aStudy did not use a control group, but reports that the prevalence is not 
statistically different from the general population
b0.17% prevalence among controls, which did not reach statistical significance
c0.02% prevalence among controls, which did not reach statistical significance
Table 28: Immune Thrombocytopenic Purpura and SIgAD
Year Reference Count
ry
Sampl
e Size
Disease
Prevalence
among
SIgAD (%)
1980 [24] Italy 35 5.71
2004 [81] USA 127 5.51
2009 [82] Icelan
d
43 2.33
2012 [20] Spain 330 0.9
2012 [93] Turkey 118 0.8
2015 [39] Iran 63 0
2017 [40] Iran 60 0
Weigh
ted
Avera
ge
1.79
Table 29: Autoimmune Hemolytic Anemia and SIgAD
Year Reference Count
ry
Sampl
e Size
SIgAD
Prevalen
ce
among
AIHA (%)
Disease
Prevalence
among
SIgAD (%)
2004 [81] USA 127 3.94
2008 [64] Brazil 126 2.38
2009 [86] Iran 37 2.7
2011 [183] France 113 17
2012 [20] Spain 330 0.61
2013 [87] Iran 26 15.38
2015 [1] Iran 57 5.26
2015 [39] Iran 63  0
2017 [40] Iran 60  0
Weigh
ted
Avera
ge
2.18
